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Background: It is shown that low-dose computed tomography (CT) screening is useful for a reduction in lung-
cancer-specific mortality in heavy smokers. However, the information about effectiveness according to the
histological types of lung cancer has not been adequately investigated especially small cell lung cancer (SCLC). The
present study was performed to see the clinical benefit of CT screening in patients with SCLC following
thoracotomy.
Methods: We retrospectively reviewed the outcome in patients with early stage SCLC who initially underwent
thoracotomy. The clinical stages and actuarial survival were estimated according to the three means of detection of
SCLC: chest CT, radiographic screen, and symptomatically prompted cases.
Results: Sixty-nine patients (men/women, 63/6; mean age, 70 years) with SCLC underwent thoracotomy between
1991 and 2010 including chest CT (n = 13), radiographic screening (n = 39), and symptomatically prompted cases
(n = 17). Pathological staging information included stage IA (n = 25), IB (n = 8), IIA (n = 13), IIB (n = 5), IIIA (n = 11),
and IIIB (n = 7). Median survival time was 30.0 (95% confidence interval (CI): 22.0 to 57.0) months, with overall
survival at 5 years of 34.3% (95% CI, 23.47 to 47.3). Nine patients (69%) with stage I were detected by CT which was
significantly higher than those in other detection arms. However, there were no significant differences in the
survival between CT and other detection arms.
Conclusions: CT examination may be useful for detection in early stage SCLC potentially suitable for surgery, but
the contribution to better clinical outcome in patients with SCLC remains unclear.
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Lung cancer is the leading cause of cancer mortality
worldwide [1], including Japan [2]. Small cell lung cancer
(SCLC) represents 10% to 15% of all lung cancers [3] and
shows a high grade of malignancy with rapid growth and
early widespread metastasis. As it is a virulent disease with
high metastatic potential, it is usually considered a sys-
temic disease at initial presentation. However, surgical re-
section has been commonly accepted in the management* Correspondence: tomonobu@shinshu-u.ac.jp
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reproduction in any medium, provided the orof the early stage of limited-disease (LD) SCLC [4]. Based
on several institutional analyses [5-9] and population-
based registration data [10-12], positive and favorable
survival rates with initial surgery have been reported in
selected patients with early stage SCLC.
On the other hand, the National Lung Screening Trial
(NLST), a large randomized controlled trial designed to
evaluate low-dose computed tomography (CT) screening
for lung cancer in heavy smokers, demonstrated a de-
crease in lung-cancer-specific mortality in a CT screening
population [13-15]. In addition, there have been many
reports that CT can detect more of these lesions at an
earlier stage than chest radiography [15,16]. We initially
began a low-dose CT screening trial using a mobile CTl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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has now been extended in Nagano Prefecture, Japan. We
previously reported six cases with early stage SCLC
detected by CT screening; four of these cases were suc-
cessfully treated by initial surgical resection [18]. Thus,
CT screening may influence the clinical outcome in pa-
tients with SCLC. Recently, Cuffe et al. [21] summarized
10 cases of SCLC identified in the CT screening and sug-
gested the ineffectiveness of CT screening because of their
identical survivals with those in general SCLC patients.
However, there remains to be a scarcity of data focusing
on screen-detected SCLC.
There were two objectives in our present study. First, we
performed a retrospective review of SCLC patients who
initially underwent surgical resection at three main hos-
pitals in Nagano Prefecture and summarized the clinical
characteristics. In addition, we divided patients according
to the initial presentations or reasons for detecting diseases
into the following three categories: chest CT, radiographic
screen, and symptomatically prompted cases. Finally, we
examined and analyzed the clinical stage and survival out-
comes according to the three categories.
Methods
Between January 1991 and December 2010, thoracotomy
was performed in a total of 3,776 cases of primary lung
cancer at Shinshu University (1,535 cases), Saku Central
Hospital (1,576 cases), and Chushin Matsumoto Hospital
(665 cases). Among them, 69 cases of SCLC (1.8%, of
total thoracotomy for patients with primary lung can-
cer), who were initially treated for SCLC by pulmonary
resection, were enrolled in the present study. There were
11 cases of SCLC treated by surgery after systemic chemo-
therapy, but these subjects were excluded from the ana-
lysis. The study subjects were identified and selected
retrospectively from operation lists and the electronic clin-
ical record search engine of hospitals. This study was
conducted according to the principles of the Declaration
of Helsinki. Patient privacy was protected when using in-
dividual information.
Clinical staging was evaluated by standard examination.
All patients underwent physical examination, complete
blood cell count, biochemistry examination, chest radio-
graphy (CXR), CT scans of the thorax and abdomen, bone
scintigraphy, and magnetic resonance imaging (MRI) scan
of the brain as pretreatment evaluation. Routine integrated
positron emission tomography (PET)/CT scan was added
to assess lymph node (and distant) involvement from 2005.
Clinical and pathological staging were performed according
to the 6th edition of the TNM classification of lung cancer.
Routine mediastinoscopy was not performed in any cases.
Operative indication was considered for clinical stages IA
to IIB in patients with preoperative diagnosis of SCLC.
With regard to diagnosis, routine fiberscopic bronchoscopycombined with transbronchial needle aspiration, forceps
biopsy, brushing, and washing or percutaneous needle
biopsy was performed if possible. However, when histo-
logical or cytological findings could not be obtained despite
these examinations or when there was a strong suspicion
of malignancy based on the CT findings, thoracotomy was
recommended. In addition, when CT scans were indeter-
minate for lesions, such as those <10 mm, follow-up CT
examinations were performed every 3 months to deter-
mine whether there were any interval changes in size,
density, configuration, or internal structures. The interpret-
ation of CT images was based on commonly used imaging
features, that is, morphological characteristics and interval
growing tendency [15,19,22]. Thus, when growing ten-
dency in the nodules was definitely identified at the annual
repeat CT screen, surgical resection was also recom-
mended. In the absence of preoperative diagnosis, patho-
logical examination was first determined intraoperatively,
and in cases in which a diagnosis of malignancy was con-
firmed we proceeded immediately to extended resection of
lung and lymph nodes. Systematically hilar and mediatinal
lymph node dissection was performed in cases of lobec-
tomy and pneumonectomy. Hilar and subcarinal lymph
node (if necessary) sampling were done in case of partial
resection. Final pathological diagnosis and stage were
established based on the resected specimen and lymph
nodes. Cases of large cell neuroendocrine carcinoma or
mixed with non-SCLC were excluded from the present
analysis.
The survival rates of the patients were calculated from
the operation date until the time of death. Survival for
all patients was recorded up to 31 July 2011. Operative
mortality was defined as death within 30 days of ope-
ration or during the same hospitalization period.
Statistical analysis
Statistical calculations were performed using StatView and
SAS (SAS Institute, Inc., Cary, NC, USA). The actual over-
all survival rates after surgery were calculated using the
Kaplan-Meier method, and differences in the resulting dis-
tributions were compared between groups by the log-rank
test. Prognostic factors for overall survival were examined
by the Cox proportional hazard model with adjustment
for covariates, including sex, pathological stage, tumor size
(>20 mm vs. ≤20 mm), lymph node metastasis status,
post-chemotherapy (yes or no), type of resection, time
period (1991 to 2000 vs. 2001 to 2010) and reason for
admission (CT screen vs. CXR screen or symptomatic
presentation). The numerical data in three groups were
compared by analysis of variance with corrections for
multiple comparisons (Scheffé’s test). Category data were
analyzed using the chi-square test. The data are expressed
as means ± standard deviation. In all analyses, P <0.05 was
taken to indicate statistical significance.
Table 1 Patient characteristics (total of 69 cases)
Mean age 70.0 (45 to 82 years)




(Mean pack year 62.1 ± 4.3)
Stage Clinical Pathological
IA 36 (52.2%) 25(36.3%)
IB 12 (17.4%) 8 (11.6%)
IIA 6 (8.7%) 13 (18.8%)
IIB 4 (5.8%) 5 (7.2%)
IIIA 8 (11.6%) 11 (15.9%)
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Clinical characteristics
The patient characteristics are shown in Table 1. The
mean age was 70.0 years (range, 45 to 82 years). The study
population consisted of 63 men (91.3%) and six women.
Five of the six female patients were never smokers, but
the others were smokers with a mean number of packs
year of 62.1 ± 4.3. The pathological staging information
included 25 patients with IA, eight with IB, 13 with IIA,Table 2 Relationship between clinical and pathological stage
IA IB IIA
Clinical stage IA 23 2 8
(T1→T2) (N0→N1)







Parentheses indicated the differences in N- and T-factors between clinical and pathfive with IIB, 11 with IIIA, and seven with IIIB. Lobectomy
was performed in 53 patients (76.8%), pneumonectomy
was performed in three patients (5.0%), and segmen-
tectomy or partial resection was performed in 13 patients
(18.8%). Partial resection was done in elderly patients or
cases with combined diseases such as chronic obstructive
pulmonary disease, interstitial pneumonitis, or a history of
prior thoracic surgery. Nine of 13 patients received partial
resection were considered to be clinical stage IA and the
stage was identical with the pathological stage in six pa-
tients. In preoperative evaluation, 40 cases were not con-
firmed histologically to be malignant. Preoperatively, there
were nine and three patients with clinical stages IIIA and
IIIB, respectively. Among the patients with IIIA, five pa-
tients were not confirmed to be malignant preoperatively,
and four had suspected non-SCLC cytologically. For these
patients, lobectomy and pneumonectomy were performed
in eight patients and one patient, respectively. One patient
with clinical stage IIIB had diagnosed as non-SCLC (squa-
mous cell carcinoma) and performed pneumonectomy.
However, other two patients with clinical stage IIIB, were
not confirmed to be malignant preoperatively, and partial
resection for the diagnosis was performed in the re-
maining two patients.
Postoperatively, 41 patients were treated with chemo-
therapy. By 1998, alternating cyclophosphamide/doxorubi-
cin/vincristine with cisplatin/etoposide chemotherapy was
performed. Subsequently, cisplatin/etoposide or cisplatin/
CPT-11 was performed after resection. Chemotherapy
was repeated for two to four cycles. There were no pa-
tients treated with adjustment thoracic radiotherapy for
hilar-mediastinal area after surgery. The postoperative
period was uncomplicated and there were no cases of
postoperative in-hospital mortality. However, one patient
developed pneumonia and died 2 months after surgery.s in SCLC initially treated with thoracic surgery
Pathological stage
IIB IIIA IIIB












ological stages in mismatched patients (n = 23).
Figure 1 Overall survival in patients with initially resected SCLC in the present study. The median survival period was 30.0 (95% CI, 22.0 to
57.0) months with an overall survival (95% CI) at 5 years of 34.3% (95% CI, 23.47 to 47.3).
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We evaluated the relationships between clinical and
pathological stages in 69 cases and the data are summa-
rized in Table 1. Only two patients were overestimated
in T- (clinical IB) and N-factor (clinical IIA) in patients
with pathological IA stage, respectively. However, the
clinical stage in 21 patients was underestimated; thus,
the accuracy was 66.7%. The differences in N- and T-
factors between clinical and pathological stages in the 21Figure 2 Comparative analysis of overall survival according to the pa
stage IA and stage I (IA+IB) were significantly longer than that in stag
Comparative analysis of overall survival according to N-factors indicated th
N1-3 (C, P <0.0012). The survival in patients with N0-1 was also longer thanpatients are shown in Table 2. Thirteen of the 36 cases
in clinical stage IA were underestimated. Differences in
N-factor were observed in 16 patients, which was 23.2%
of all subjects. The change in T-factor to T4 was due to
pleural dissemination.
Survival analysis
The overall survival curve is shown in Figure 1A. Me-
dian survival time and 5-year survival rate were 30.0thological stage revealed that the survival periods in patients
e IIIB (A, IA vs. IIIB, P <0.026; B, I vs. IIIB, P <0.019, respectively).
at the survival in patients with N0 was significantly longer than that in
that in N2-3 (D, P <0.0011).
Table 3 Numbers of patients with SCLC initially treated
with thoracic surgery according to CT test, radiographic
screen (CXR), and symptomatically prompted cases
Symptoms (n=17) CXR (n=39) CT (n=13)
Stage IA (n = 25) 4 (23.5%) 13 (33.3%) 8 (61.5%)a
Stage IB (n = 8) 1 (5.9%) 6 (15.4%) 1 (7.7%)
Stage IIA (n = 13) 3 (17.6%) 8 (20.5%) 2 (15.4%)
Stage IIB (n = 5) 1 (5.9%) 4 (10.3%) 0
Stage IIIA (n = 11) 3 (17.6%) 8 (15.4%) 0
Stage IIIB (n = 7) 5 (29.4%) 0 2 (15.4%)
aVs. symptoms (P <0.05).
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34.3% (95% CI, 23.47 to 47.3), respectively (Figure 1).
According to the pathological stages in patients with
resected SCLC, the median survival time and 5-year sur-
vival rate were 30 months (95% CI, 20.5 to 97.0) and
43.1% (95% CI, 26.5 to 61.5) in stage 1, 56.9 months
(95% CI, 19.0 to 148.0) and 37.8% (95% CI, 17.6 to 63.4)
in stage II, and 27.3 months (95% CI, 10.3 to 52.0) and
17.7% (95% CI, 5.8 to 42.8) in stage III, respectively.
There were no statistically significant differences in over-
all survival among the three stages. However, survival pe-
riods in patients stages IA and I (IA+IB) were significantly
longer than those in stage IIIB (IA vs. IIIB, P <0.026,
Figure 2A, I vs. IIIB, <0.019, Figure 2B). In addition, in
terms of N-factor, survival periods in patients with N0 and
N0-1 were significantly longer than those in patients with
N1-3 (N0 vs. N1-3, P <0.0012, Figure 2C) and N2-3 (N0-1
vs. N2-3, P <0.0011, Figure 2D), respectively. On the other
hand, there were no significant differences between T1
and other T-factors (P <0.06). Furthermore, we dividedFigure 3 Comparative analysis of the overall survival between patien
radiographic screening test and symptomatic patients) showed no sttumor diameter into >20 mm vs. ≤20 mm, but there were
no significant differences in survival between tumors of
these two size ranges (P >0.50). Thus, the tumor size
(T-factor) was not independent prognostic factor in pa-
tients with SCLC who were initially treated by thoracic
surgery. We also analyzed the survival according to CT,
CXR screen, and symptomatically prompted groups.
Table 3 shows the number of patients in each pathological
stage according to CT, CXR screen, and symptomatically
prompted groups. Eight patients in the CT group were
detected by CT screening. Five cases of SCLC were inci-
dentally detected by chest CT due to the other diseases in-
cluding postoperative follow-up for other malignant
diseases or pulmonary diseases. There was no significant
difference in the frequency and distribution of each stage
between the CT group. Eight cases in CT group were stage
IA, which was significantly higher than other groups. Sur-
vival curves in the CT group and other groups are shown
in Figure 3. Survival in the CT screen group was better
than in the chest CXR screen and symptomatically
prompted groups, but the differences were not significant
(P <0.37). Thus, there were no significant differences in
survival among the three groups. In addition, there were
no significant differences in survival related to sex, post-
chemotherapy, type of resection, and time period between
the first and later half (data not shown).
Discussion
We summarized the clinical outcomes in patients initially
underwent surgical resection for SCLC and demonstrated
a 5-year survival rate of 34.3%. Several recent retrospective
analyses have described improved or favorable survival
rates in patient with resected SCLC [5-12]. Chandra et al.ts detected by computed tomography (CT) and others (chest
atistically significant difference between the two groups.
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disease, who underwent thoracotomy for SCLC at their
own institution and described an overall 5-year survival
rate of 27%. Lim et al. [9] recently described excellent re-
sults a 5-year survival rate of 52% for patients with stage I
to III disease who underwent lung resection. In their
series, there were no clear differences in clinical categories
or across the spectrum of nodal disease from N0 to N2. In
Japanese subjects with resected SCLC, 5-year survival rate
was 43% and the survival has improved over the past
several decades [8]. In addition, Schreiber et al. [11] sum-
marized treatment arms and overall survival in patients
with LD-SCLC using a US population-based database,
and compared survival with and without surgery. They
reported that 5-year survival rates in both T1-2, N0 and
T3-4, N0 or T1-4, N1-2 were significantly higher in pa-
tients treated with than those in those without surgery
(44.8% and 26.3% vs. 13.7% and 9.3%, respectively). Thus,
surgery was associated with improved survival for selected
patients with early stage SCLC. In our series, survival
results and disease distribution were almost identical to
these previous studies [5-12]. Thus, we also suggest that
good results can be achieved in selected patients with
complete resection throughout the spectrum of UICC
from stage I to III. These results, including our data, do
not suggest that we should routinely perform surgery in
all patients in stages I to III. However, we feel that surgery
could have an important role in the treatment strategies
in patients in the early stages of LD-SCLC.
In the present study, N-factor rather than T-factor was
an important prognostic factor in patients with SCLC who
underwent initial thoracic surgery, which was consistent
with previous studies [11,12,23]. Thus, an accurate pre-
operative diagnosis of the N-status should be made to
determine indications for surgery in patients with SCLC.
We found that the N-factor was underestimated in 16
patients in the present study. Similar findings of mismatch
with nodal involvements between pre- and post-surgery
were also reported in other studies [7,9,23]. Real-time
endobronchial ultrasound-guided transbronchial needle
aspiration (EBUS-TBNA) and PET/CT are new diagnostic
tools and have been shown to be useful for precise diagno-
sis and staging of lung cancer, especially N involvements
[24,25]. As EBUS-TBNA and PET/CT are now available
for routine use in our institutes, the time frame of this 20-
year retrospective analysis could influence the current
data, which may be a limitation of the present analysis.
Further studies are required to determine how N2 disease
can be accurately diagnosed and excluded from surgery in
patients with SCLC.
The present study focused on comparisons of staging
and survival in initial resected SCLC according to the
reasons for detecting disease, that is, CT and radiographic
screening or symptoms. We found that a frequency ofstage I SCLC in a CT detected population was signifi-
cantly higher than those in other groups, but patients
detected by CT had no better survival benefit compared
with those detected by chest radiographic screening and
symptomatically prompted patients. The prospective study
of NLST demonstrated that the use of CT screening re-
duced mortality from lung cancer in heavy smokers
[13-15]. However, CT screening identified a preponder-
ance of early stage adenocarcinoma. Although survival
analysis according to histological type was not described
in the NLST study, there were no significant differences in
detection of patients with SCLC in each stage between CT
and radiographic screening groups [13]. The present study
was limited to patients with initially resected SCLC and
evaluated prospectively. Furthermore, CT group included
five cases of SCLC accidentally detected by follow-up CT
examination for other diseases. Thus, it is difficult for us
to comment the role of CT screening on the prognosis in
patients with SCLC from the present results. However, our
data suggested that CT examination could bring a stage
shift to early disease in SCLC who was considered for sur-
gery. Further studies comparing the clinical outcomes of
all stages of SCLC detected by radiographic screening with
symptomatically prompted cases are required.
Conclusions
Retrospective analysis of surgical results for SCLC sug-
gested that operation should be considered for early stage
SCLC. However, accurate preoperative diagnosis, especially
N2 status, is required. In addition, CT screening may con-
tribute to detection of early stage SCLC suitable for tho-
racic surgery but it remains unclear whether CT screening
can improve clinical outcome in patients with SCLC.
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